Cleerly Raises $192 Million To End Heart Disease With AI
Cleerly, a company envisioning a world without heart disease, has raised a huge $192 million to do just that with the power of AI.
Created on July 25|Last edited on July 25
Comment
Heart disease is the leading cause of death globally, and often takes lives with no warning. Many of the specific damages present in the heart that cause heart attack are never caught by conventional testing, and in half of heart attack cases, patients have never exhibited any symptoms which might indicate one is coming.
Cleerly envisions a world free from heart attacks. They have developed a powerful AI-based solution to detect indicators of heart disease more thoroughly than traditional methods, and protect patients' lives long before it's too late. Their AI analyzes coronary CT angiograms to find any dangerous plaque buildups that may lead to heart attacks in the future.
Who's funding Cleerly and where's the money going?
Cleerly has announced today that they have raised a huge $192 million in a Series C funding round. The funding round also had quite a large investor turnout.
The leading investors were T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, Inc., and Fidelity Management and Research Company.
Other participating investors were Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, Novartis, Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures and DigiTx Partners.
They plan to use the money to grow their team and commercial reach, as well as investing in further outcomes research.
Find out more
Add a comment
Tags: ML News
Iterate on AI agents and models faster. Try Weights & Biases today.